Open-label Randomized Multicenter Trial to Evaluate the Impact on the Lipid Profile of the Substitution of the NRTIs of a HAART Regimen by a Once Daily Fixed Dose Combination Tablet of Emtricitabine and Tenofovir DF Versus Maintained Treatment in HIV Infected Controlled Patients.

Trial Profile

Open-label Randomized Multicenter Trial to Evaluate the Impact on the Lipid Profile of the Substitution of the NRTIs of a HAART Regimen by a Once Daily Fixed Dose Combination Tablet of Emtricitabine and Tenofovir DF Versus Maintained Treatment in HIV Infected Controlled Patients.

Completed
Phase of Trial: Phase IV

Latest Information Update: 18 Jan 2010

At a glance

  • Drugs Emtricitabine; Nucleoside reverse transcriptase inhibitors; Tenofovir disoproxil fumarate
  • Indications HIV infections
  • Focus Pharmacodynamics
  • Acronyms TOTEM
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 18 Jan 2010 Results were presented in the Journal of Antimicrobial Chemotherapy.
    • 29 Dec 2009 Actual end date changed from Aug 2008 to Mar 2008 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top